Coventry Terminates Deal with Sequenom; Further Data Published on MaterniT21 Plus Test | GenomeWeb

NEW YORK (GenomeWeb News) – Coventry Health Care National Network has terminated its coverage agreement with Sequenom covering the MaterniT21 Plus test, just one week after the agreement was announced, the San Diego-based molecular diagnostics firm said after the close of the market on Thursday.

Coventry told Sequenom that the termination was without cause and was not a judgment on Sequenom, its Sequenom Center for Molecular Medicine subsidiary — which administers the non-invasive test for fetal aneuploidies — or its products, Sequenom said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.